retatrutide nonalcoholic fatty liver disease nash trial steatohepatitis in Patients with Type 2 Diabetes: Screening, Diagnosis, and Treatment Oligonucleotide therapies for nonalcoholic steatohepatitis – retatrutide nonalcoholic fatty liver disease

Do not try to mask the taste with food, drink, or mouthwash before the 30-minute post-dose fasting window

Do not exceed one dose per 24 hours or eight doses per month

Perfect technique at a moderate dose often outperforms sloppy technique at a higher dose

Dec 18, 2025, 08:00 ET CagriSema 2.4 mg/2.4 mg is an investigational fixed-dose injectable medicine that combines the novel amylin analogue, cagrilintide, with semaglutide to target complementary obesity-related pathways 1,2 In the REDEFINE 1 phase 3 trial, adults with obesity, or overweight with at least one obesity-related complication, taking CagriSema lost an average of 23% body weight when evaluating the treatment effect if all patients stayed on treatment *2 Novo Nordisk continues to build on its 100-year-plus legacy of science and innovation, with potential new treatments in obesity PLAINSBORO, N.J